BioNTech SE NASDAQ: BNTX niemiecka spółka biotechnologiczna i farmaceutyczna m.in. szczepionka na COVID

[slayer74]

Latest Release
Nov 09, 2021

EPS / Forecast
12.35 / 10.54

Revenue / Forecast
6.09B / 5.1B

[slayer74]

BioNTech celuje w 17 mld EUR przychodów z produkcji szczepionek w 2022 roku

https://www.pb.pl/biontech-celuje-w-17- ... ku-1138298

[slayer74]

BioNTech (NASDAQ:BNTX) stock rose 6.7% after the drugmaker beat fourth quarter estimates, helped by surging cash flows from its Covid-19 vaccines, while announcing a special dividend and a likely share buyback of up to $1.5 billion.

[slayer74]

BioNTech Soars on Q4 Beat, Special Dividend, Promise of Buyback

Investing.com – BioNTech (NASDAQ:BNTX) stock gained 8% in premarket trading Wednesday after the company beat fourth-quarter estimates and promised to channel its surging cash flows from its life-saving Covid-19 vaccines into the research of similar therapies for oncology and other infectious diseases.

A special dividend of 2 euros per share and a likely buyback of up to $1.5 billion worth of shares were also adding to the gains in the stock. The company expects to authorize the share repurchase plan that will be executed over two years.

The company expects its Covid-19 vaccines to generate sales of anywhere between 13 billion euros and 17 billion euros. That will be less than the 19 billion euros the company booked in 2021 and indicates a slight softening of demand with much of the world’s population vaccinated with at least one dose. The virus is also expected to weaken with most of the world having had at least two surges since 2020.

Revenue in the final quarter was 16 times higher at 5.53 billion euros, riding on the unique mRNA technology in the company's vaccines that saved millions of lives the world over. Under collaboration agreements, territories have been allocated amongst BioNTech, Pfizer (NYSE:PFE), and Fosun Pharma (HK:2196) based on marketing and distribution rights. Gross profits are shared between the companies.

As of mid-March, BioNTech and Pfizer have signed orders for nearly 2.4 billion doses in 2022, the former said in a release. As of the beginning of this month, they have so far delivered more than 3.1 billion doses of BNT162b2 to more than 170 countries.

Net profit in the quarter was 3.16 billion euros.

The company said it is developing the next generation of Covid-19 vaccines while fully leveraging the potential of all technology platforms across autoimmune diseases, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, and regenerative medicines.

[slayer74]

Latest Release
May 09, 2022

EPS / Forecast
14.24! / 9.17

Revenue / Forecast
6.37B / 4.34B

[slayer74]

Vaccine maker BioNTech (BNTX) doubled Wall Street's third-quarter profit expectations Monday and raised its full-year outlook for Covid vaccine sales. BNTX stock rose 1%, erasing early losses.

The Germany-based company reported earnings of 6.98 euros per share on 3.46 billion euros in sales. Based on today's exchange rates, earnings were about $6.98 per share and sales came out to $3.46 billion. Both metrics handily beat expectations, according to FactSet.

[slayer74]

Latest Release
Mar 27, 2023

EPS / Forecast
9.26 / 8.12

Revenue / Forecast
4.28B / 3.78B

[slayer74]

BioNTech is also in the spotlight as a court case is set to start in Germany, with a woman alleging damaging side effects from the biotech’s COVID-19 vaccine - a lawsuit that could have widespread repercussions.

[slayer74]

Latest Release
Aug 07, 2023

EPS / Forecast
-0.79 / -0.83

Revenue / Forecast
167.7M / 607.8M